News for 'Research Development and Standard'

Issey Miyake Was Nothing Short Of Genius

Issey Miyake Was Nothing Short Of Genius

Rediff.com31 Aug 2022

'Known for his innovative styles and perfumes, Issey Miyake built a global fashion brand, which included designing Steve Jobs' famous black turtle neck jumpers.'

Explained: What USFDA full approval to Pfizer-BioNTech vaccine means

Explained: What USFDA full approval to Pfizer-BioNTech vaccine means

Rediff.com17 Sep 2021

Pfizer can show the FDA approval to the Indian regulator and present a case that based on whatever data submitted, the US regulator has granted a full marketing nod, says Sohini Das.

Bharat Biotech asked to submit phase 2 data of its Covid vaccine

Bharat Biotech asked to submit phase 2 data of its Covid vaccine

Rediff.com10 Oct 2020

The vaccine candidate -- 'Covaxin' -- is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

HAL gets cracking on Tejas Mark 2

HAL gets cracking on Tejas Mark 2

Rediff.com6 Jan 2022

HAL is also integrating the Advanced Short Range Air-to-Air Missile onto the Mark 1A. Each Tejas will carry two of these missiles.

India's first mRNA vaccine gets nod for human trials

India's first mRNA vaccine gets nod for human trials

Rediff.com12 Dec 2020

The novel mRNA vaccine candidate, HGCO19, is supported with seed grant under the Ind-CEPI mission of the Department of Biotechnology. The mRNA vaccines do not use the conventional model to produce immune response. Instead, they carry molecular instructions to make the protein in the body through a synthetic RNA of the virus.

'A Global Recession Can Be Avoided'

'A Global Recession Can Be Avoided'

Rediff.com4 Oct 2022

'We continue to believe that the global economy will narrowly avoid a recession, despite expecting the US, Canada, and most of Europe to fall into recession at some point over the next year or so.'

TCS opens special R&D centre in Hyderabad

TCS opens special R&D centre in Hyderabad

Rediff.com16 Jun 2015

The centre will be focusing on emerging communication technologies

Serum Institute ready to roll out Covid vaccine

Serum Institute ready to roll out Covid vaccine

Rediff.com3 Jan 2021

The Pune-based vaccine major has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.

Why India is unlikely to double farmers' income

Why India is unlikely to double farmers' income

Rediff.com2 May 2022

Earlier this month, the Central government said in a reply in Parliament it had taken measures to double farmers' income by the end of FY23 and the progress made so far indicated it was "on the right track". However, a close look at the data and at the assumptions made shows that as of now, it appears the country is unlikely to achieve the goal in real terms.

33 of 95 BSE100 cos INCREASED CAPEX

33 of 95 BSE100 cos INCREASED CAPEX

Rediff.com4 Feb 2021

Acquisitions may have played a role in much of the increase.

'Drone attacks are an evolving threat'

'Drone attacks are an evolving threat'

Rediff.com23 Jul 2021

'India needs offensive and defensive security measures to protect itself.'

'India is in the mid of a compelling investment cycle'

'India is in the mid of a compelling investment cycle'

Rediff.com22 Dec 2021

'Good investment opportunities should not be missed.'

Ease fiscal deficit, look at higher spend for future: Assocham president to FM

Ease fiscal deficit, look at higher spend for future: Assocham president to FM

Rediff.com18 Jan 2021

As spending on infrastructure has three times the desired impact, the government's Rs 111 trillion National Infrastructure Pipeline should be accelerated: Assocham president, Vineet Aggarwal

Patanjali didn't have permission for COVID-19 drug: Uttarakhand govt

Patanjali didn't have permission for COVID-19 drug: Uttarakhand govt

Rediff.com25 Jun 2020

State Ayurved Department's licence officer Y S Rawat said the notice is being issued to the firm to explain from where it got the permission to launch a 'corona kit' as a cure from the virus.

Why You Need To Invest

Why You Need To Invest

Rediff.com22 Jun 2022

Saving for your future, older self is one of the main reasons why you should invest. Since one day you will either be unwilling or unable to work, investing allows you to have a pool of resources you can draw upon in old age.

Oxford Covid vaccine under lens after error: Report

Oxford Covid vaccine under lens after error: Report

Rediff.com26 Nov 2020

AstraZeneca Plc and the University of Oxford are facing questions about their Covid-19 vaccine and whether regulators would quickly authorise its emergency use after the pharma company acknowledged an error in the vaccine dosage received by some participants and other irregularities and omissions, according to the New York Times.

More Covid vaccine candidates get approval for clinical trials in India

More Covid vaccine candidates get approval for clinical trials in India

Rediff.com6 Feb 2021

Ahmedabad-based Zydus Cadila, Bharat Biotech's intra-nasal candidate are among the candidates who got approval from the expert panel to conduct clinical trials, Sohini Das reports.

'Key risks to markets in 2022 are...'

'Key risks to markets in 2022 are...'

Rediff.com16 Dec 2021

'Overtightening of monetary policy by central banks and the spread of new Covid variants, which may force governments to restart lockdowns or restrict mobility.'

Covid vaccine possible by 2021 first quarter: Vardhan

Covid vaccine possible by 2021 first quarter: Vardhan

Rediff.com13 Sep 2020

Vardhan stated the government is taking full precautions in human trials of vaccines and the National Expert Group on Vaccine Administration for COVID-19 under the chairmanship of Dr V K Paul, member-health, NITI Aayog, is drawing up a detailed strategy on how to immunize the majority of the population.

Why Doctors Stopped Being Gods

Why Doctors Stopped Being Gods

Rediff.com15 Sep 2022

I got to know that every referred case for angiography and angioplasty got a kickback of Rs 5,000 and Rs 15,000 respectively. Seeing this trend, doctors started paying referring doctors Rs 1 lakh in advance and adjusting it as and when patients came in. This menace slowly spread its tentacles all over the medical field, including radiological diagnostics and biochemistry laboratories. For every test ordered, 20 per cent of the bill was given back to the referring doctor. This led to doctors recommending unnecessary tests. The pharmaceutical companies also saw burgeoning business. Acclaimed doctors were given televisions sets, refrigerators, air conditioners and cars depending upon the prescriptions. General practitioners would prescribe unnecessary drugs, and were given returns in cash. A fascinating excerpt from Dr Upendra Kaul's When The Heart Speaks.

'BJP is focused on economic growth'

'BJP is focused on economic growth'

Rediff.com2 Feb 2022

'I see in the BJP an attempt to get growth and redistribution of resources.' 'For growth you need growth of the economy.'

Controversial study that claimed HCQ unsafe for COVID-19 retracted

Controversial study that claimed HCQ unsafe for COVID-19 retracted

Rediff.com5 Jun 2020

'Several concerns were raised with respect to the veracity of the data and analyses conducted by Surgisphere Corporation and its founder'

Gennova's mRNA vaccine to come in powder form, stay stable at 2-8C

Gennova's mRNA vaccine to come in powder form, stay stable at 2-8C

Rediff.com14 Sep 2021

Gennova has also got permission for phase-2 and 3 clinical trials for its lyophilised mRNA vaccine for injection from the subject expert committee advising the Central Drugs Standards Control Organisation, reports Sohini Das.

Vaccine trials: Bharat Biotech recruits 23,000 volunteers

Vaccine trials: Bharat Biotech recruits 23,000 volunteers

Rediff.com3 Jan 2021

Covaxin is being developed by Bharat Biotech jointly with the Indian Council of Medical Research (ICMR)- National Institute of Virology (NIV). The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers and it is the country's first and only Phase III efficacy study for a COVID-19 vaccine, a press release from the vaccine maker said on Saturday night.

Why Pakistan, Bangladesh, Nepal have lower Covid mortality rates than India

Why Pakistan, Bangladesh, Nepal have lower Covid mortality rates than India

Rediff.com16 May 2022

An analysis of WHO data shows that most of the countries with an older cohort of population and higher in the development index had a lower excess mortality rate than India.

'I am bullish on India'

'I am bullish on India'

Rediff.com11 Feb 2022

'India has many attractive features for the long-term investor; it combines: A low per capita income, a young population, and a heavier presence of high margin, asset-light firms in the technology sector.'

Expert panel seeks more data on SII, Bharat Biotech vaccines

Expert panel seeks more data on SII, Bharat Biotech vaccines

Rediff.com10 Dec 2020

An expert committee of the Central Drugs Standard Control Organisation (CDSCO) on Wednesday sought additional safety and efficacy data for COVID-19 vaccine candidates of Serum Institute and Bharat Biotech, after deliberating upon their applications seeking emergency use authorisation for the shots, official sources said.

COVID-19 second wave: Delays in RT-PCR tests

COVID-19 second wave: Delays in RT-PCR tests

Rediff.com9 May 2021

While there is a shortage of testing kits, manpower and capacities, India does not have other scalable testing options.

Lockdown tamed doubling rate of COVID-19 cases: Health ministry

Lockdown tamed doubling rate of COVID-19 cases: Health ministry

Rediff.com17 Apr 2020

Joint Secretary in the Health Ministry Lav Agarwal claimed that India has been doing better than many other countries on the outcome ratio, which is the number of recoveries from coronavirus infection versus the number of deaths.

'BJP and Yogi never had good relations'

'BJP and Yogi never had good relations'

Rediff.com9 Feb 2022

'Since 2017, the chief minister and the RSS seem to have come closer.' 'This relationship's warmth is more from the RSS's side.'

Sputnik V vaccine 92% 'effective' against coronavirus, claims Russia

Sputnik V vaccine 92% 'effective' against coronavirus, claims Russia

Rediff.com11 Nov 2020

The efficacy of the vaccine, developed by the Gamalaya Centre, was demonstrated on the basis of a first interim analysis obtained 21 days after the first injection.

Army to purchase more lethal Arjun tanks

Army to purchase more lethal Arjun tanks

Rediff.com14 Apr 2010

New Arjuns will fire anti-tank missiles; have extra armour protection

Over 73.5 lakh tested for Covid so far, 2.15 lakh in 1 day: ICMR

Over 73.5 lakh tested for Covid so far, 2.15 lakh in 1 day: ICMR

Rediff.com24 Jun 2020

The apex health research body on Tuesday validated the 1,000th testing laboratory, ramping up the capacity for detection of COVID-19 in the country. Currently, three lakh samples can be tested per day, an official said.

HSBC's cost-cutting may lead to job losses in India

HSBC's cost-cutting may lead to job losses in India

Rediff.com10 Oct 2019

As many as 40 staffers, in the key equities and investment banking division in India, could be asked to go as part of the London-headquartered lender's global layoffs, said people aware of the development. HSBC India declined to comment.

Modi and Nehru Are Similar, Yet...

Modi and Nehru Are Similar, Yet...

Rediff.com26 Jan 2022

Modi's critics will say that he has put up cement and steel structures, but weakened the institutions of governance whereas Nehru strengthened them, observes T N Ninan.

Bharat Biotech's Covid vaccine gets nod for Phase 3 trial

Bharat Biotech's Covid vaccine gets nod for Phase 3 trial

Rediff.com23 Oct 2020

The phase 3 clinical trial will cover around 28,500 subjects, aged 18 years and above, and it will be conducted in 21 sites across ten states, including Delhi, Mumbai, Patna and Lucknow.

Govt expects speedy launch of single-dose Sputnik Light vaccine

Govt expects speedy launch of single-dose Sputnik Light vaccine

Rediff.com27 May 2021

The government is hopeful of a speedy launch of single-dose COVID-19 vaccine Sputnik Light in India and all stakeholders, including the Russian manufacturer and its Indian partners, have been directed to fast-track the application and regulatory approval procedures for the jab to boost the country's vaccination drive, sources said.

Beware! Your 'office' coffee mug can make you sick

Beware! Your 'office' coffee mug can make you sick

Rediff.com28 Sep 2017

Even your well-cleaned coffee mug may up risk of diarrhoea, vomiting!

US gives full approval to Pfizer Covid vaccine

US gives full approval to Pfizer Covid vaccine

Rediff.com23 Aug 2021

More than 200 million Pfizer doses have been administered in the US, and hundreds of millions more worldwide, since December.

How complex is the process of getting approval for a vaccine?

How complex is the process of getting approval for a vaccine?

Rediff.com30 Sep 2020

Vaccine development is a long process to ensure safety and efficacy through different stages and involves regulatory supervision every step of the way. Ruchika Chitravanshi takes you through this carefully drawn journey of vaccine development.